Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dacinostat (NVP-LAQ824) 是一种新型 HDAC 抑制剂,IC50 为 32 nM,是 p21 启动子的激活剂。它也可抑制HDAC1的活性,IC50值为 9 nM,主要用于癌症研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 477 | 现货 | ||
2 mg | ¥ 691 | 现货 | ||
5 mg | ¥ 1,110 | 现货 | ||
10 mg | ¥ 1,730 | 现货 | ||
25 mg | ¥ 2,930 | 现货 | ||
50 mg | ¥ 4,330 | 现货 | ||
100 mg | ¥ 6,180 | 现货 | ||
500 mg | ¥ 12,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,330 | 现货 |
产品描述 | LAQ824 (Dacinostat (NVP-LAQ824)) is a novel HDAC inhibitor with IC50 of 32 nM and is an activator of the p21 promoter. |
靶点活性 | HDAC:32 nM |
体外活性 | 100 mg/kg LAQ824剂量依赖性抑制携带HCT116和人结肠癌移植瘤的裸鼠肿瘤生长,且无细胞毒性. |
体内活性 | LAQ824诱导A549细胞中p21蛋白的剂量依赖性增加和Rb肿瘤抑制因子的低磷酸化状态的增加。LAQ824在IL-10基因启动子水平诱导染色质改变,导致增强的转录抑制因子HDAC11和PU.1的募集并抑制BALB/c鼠巨噬细胞中IL-10的产生。此外,LAQ824通过激活p21启动子,也激活编码p21细胞周期抑制剂的基因表达,最大启动子活性AC50为50%时,浓度为0.30 μM。 LAQ824抑制H1299(一种非小细胞肺癌细胞系)和HCT116(一种结肠癌细胞系)的细胞生长,IC50分别为0.15 μM和0.01 μM,LAQ824的抗增殖作用对肿瘤细胞系具有选择性,同时仅在正常成纤维细胞中诱导生长停滞。 |
激酶实验 | In Vitro Histone Deacetylase Assay: HDAC enzymes are partially purified from H1299 cell lysate by ion exchange chromatography using the Q Sepharose Fast Flow column. Enzyme complexes are collected from 500 mg of total cell lysate by immunoprecipitation with cdk2 polyclonal antibody or cdk1/cdc2 monoclonal antibody. Immunoprecipitates are resuspended in kinase buffer (50 mM Hepes, pH 8, 10 mM MgCl2, 2.5 mM EDTA, 1 mM dithiothreitol, 20 mM ATP, 10 mM β-glycerophosphate, 0.1 mM NaVO4, 1 mM sodium fluoride, 50 mM ATP, 10 μCi of [γ-32P]ATP) along with 1 μg of pRb recombinant protein substrate (cdk2) or 10 mL of H1 histone mixture containing 20 μg of substrate (cdc2). Phosphorylated Rb and H1 histone are resolved by electrophoresis and quantitated using a PhosphorImager. |
细胞实验 | Cell proliferation is measured using an adaptation of published procedures (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfonyl)-2H-tetrazolium assay). The cells are seeded in 12-well dishes and cultured in RPMI 1640 containing 10% FBS. The cells are cultured in the presence of various concentrations of TSA (up to 1,000 ng/mL). To examine the growth inhibition by TSA, viable cell numbers are determined by trypan blue dye exclusion, counted in a Nesbauer-type hemocytometer for 0 hour, 24 hours, and 48 hours. The same amount of ethanol is added to the RPMI 1640 medium as the control experiment. All experiments are performed in duplicate and repeated 3 times The average background value (treatment with medium alone) is subtracted from each experimental well; triplicate values are averaged for each compound dilution. The following formulas are used to calculate the percentage of growth: If X<T0, %Growth=(X-T0)/T0*100; If X>T0, %Growth=(X-T0)/(GC-T0)*100. where T0 is the average value of T0 ? background, GC is the average value of untreated cells (in triplicate) ? background, and X is the average value of compound-treated cells (in triplicate)-background. The "% Growth" is plotted against compound concentration and used to calculate the IC50 using the linear regression techniques between data points to predict the concentration of compounds at 50% inhibition.(Only for Reference) |
别名 | NVP-LAQ824, 达西司特, LAQ824 |
分子量 | 379.45 |
分子式 | C22H25N3O3 |
CAS No. | 404951-53-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 71 mg/mL (187.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6354 mL | 13.177 mL | 26.3539 mL | 65.8848 mL |
5 mM | 0.5271 mL | 2.6354 mL | 5.2708 mL | 13.177 mL | |
10 mM | 0.2635 mL | 1.3177 mL | 2.6354 mL | 6.5885 mL | |
20 mM | 0.1318 mL | 0.6588 mL | 1.3177 mL | 3.2942 mL | |
50 mM | 0.0527 mL | 0.2635 mL | 0.5271 mL | 1.3177 mL | |
100 mM | 0.0264 mL | 0.1318 mL | 0.2635 mL | 0.6588 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Dacinostat 404951-53-7 Autophagy Chromatin/Epigenetic DNA Damage/DNA Repair HDAC LAQ 824 LAQ-824 NVP-LAQ824 NVP-LAQ 824 达西司特 NVP-LAQ-824 Histone deacetylases inhibit Inhibitor LAQ824 inhibitor